The spontaneous regression of neoplasms in mammals: Possible mechanisms and their application in immunotherapy

In Vivo

Volumn 12, Issue 1, 1998, Pages 107-122

  Bodey, Bela ^a,d   Bodey Jr , Bela ^a   Siegel, Stuart E ^b   Kaiser, Hans E ^c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d NONE   (United States)

Author keywords

Angiogenesis, and metastasis; Anticancer immunotherapy; Carcinogenesis; Hormonal SR; Immunological mechanism of SR; Neoplastic cell immunophenotype (IP) dedifferentiation; Neoplastic cell redifferentiation; Neoplastic cell transformation; Neoplastic progression; Oncogenes and growth factors; Spontaneous regression (SR)

Indexed keywords

CYTOKINE; ESTROGEN; GROWTH FACTOR; TELOMERASE;

ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL TRANSFORMATION; NATURAL KILLER CELL; ONCOGENE; T LYMPHOCYTE;

EID: 0031976263     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (220)

1. Marshall C: Tumor suppressor genes. Cell 64: 313-326, 1991.
2. Bodey B, Kaiser HE, Goldfarb RH: Immunophenotypically varied cell subpopulalions in primary and metastatic human melanomas. Monoclonal antibodies for diagnosis, detection of neoplastic progression and receptor directed immunotherapy. Anticancer Res 16: 517-531, 1996.
3. Bodey B, Gröger AM, Bodey B Jr, Siegel SE, Kaiser HE: Immunocytochemical detection of p53 protein overexpression in primary human osteosarcomas. Anticancer Res 17: 493-498, 1997.
4. Hedrick L, Cho KR, Fearon ER, Wu T-C, Kinzler KW, Vogelstein B: The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev 8: 1174-1183, 1994.
5. Perry ME, Levine AJ: Interactions between tumor suppressor gene and oncogene products. Mount Sinai J Med 61: 291-299.
6. Talib VH, Pandey J, Dhupia JS: Molecular markers in cancer diagnosis. Ind J Pathol Microbiol 38: 1-3, 1995.
7. Jacobson DR, Fishman CL, Mills NE: Molecular genetic tumor markers in the early diagnosis and screening of non-small-cell lung cancer. Annals Oncol 6 (Suppl 3): S3-S8, 1995.
8. Bugert P, Bugert P, Kovacs G: Molecular differential diagnosis of renal cell carcinomas by microsatellite analysis. Am J Pathol 149: 2081-2088, 1996.
9. Dietzmann K, von Bossanyi P, Sallaba J, Kirches E, Synowitz HJ, Warich-Kirches M: Immunohistochemically detectable p53 and mdm-2 oncoprotein expression in astrocytic gliomas and their correlation to cell proliferation. General Diagn Pathol 141: 339-344, 1996.
10. Volpe JP: Genetic instability of cancer: Why a metastatic tumor is unstable and a benign tumor is stable. Cancer Genet Cytogenet 34: 124-134, 1988.
11. Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079-1087, 1990.
12. Bodey B, Bodey B Jr, Gröger AM, Siegel SE, Kaiser HE: Clinical and prognostic significance of Ki-67 and proliferating cell nuclear antigen expression in childhood primitive neuroectodermal brain tumors. Anticancer Res 17: 189-196, 1997.
13. Bodey B, Bodey B Jr, Gröger AM, Siegel SE, Kaiser HE: Nm23/nucleoside diphosphate (NDP) kinase expression in human malignant melanomas. Significance and implications in tumor biology. Anticancer Res 17: 505-512, 1997.
14. Vogelstein B, Fearon E, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1988.
15. Sirica AE: Multistage carcinogenesis in cellular and molecular pathogenesis. Philadelphia, Lippincott-Raven, pp 283-320, 1996.
16. Pollard M, Luckert PH: Phenobarbital promotes multistage pulmonary carcinogenesis in MNU-inoculated L-W rats. IN VIVO 11: 55-60, 1997.
17. Nicolson GL: Growth mechanism and cancer progression. Hosp Prac 28: 43-53, 1993.
18. Parsons DF: Some tumor cell protein kinases activated by receptors as markers, including elastin receptors. Cancer Invest 13: 629-636, 1995.
19. Osler W: The medical aspects of carcinoma of the breast, with a note on the spontaneous disappearance of secondary growths. Am Med 17-19: 63-66, 1901.
20. Rhodenberg GL: Fluctuations in the growth rate of malignant tumors in man, with special reference to spontaneous regression. J Cancer Res 3: 193-221, 1918.
21. Rae MV: Spontaneous regression of hypernephroma. Am J Cancer 24: 839-841, 1935.
22. Everson TC, Cole WH: Spontaneous Regression of Cancer. Philadelphia, WB Saunders, pp 1-1187, 1966.
23. Cole WH: Spontaneous regression of cancer. The metabolic triumph of the host? Ann NY Acad Sci 230: 111-141, 1974.
24. Challis GB, Stam HJ: The spontaneous regression of cancer. A review of cases from 1900 to 1987. Acta Oncol 29: 545-550, 1990.
25. Papac RJ: Spontaneous regression of cancer. Conn Med 54: 179-182, 1990.
26. Kaiser HE: A biological approach to an understanding of regression. In: Cancer Growth and Progression (series ed Kaiser HE), vol 4: Influence of Tumor Development of the Host (volume ed Herberman RB), Kluwer Academic Publishers, Dordrecht, The Netherlands, p 42, 1989.
27. Kaiser HE: Biological viewpoints of neoplastic regression. IN VIVO 8: 155-165, 1994.
28. Cooper KR: Regression of neoplasms in invertebrates with special emphasis on mollusca. In: Cancer Growth and Progression (Kaiser HE, series ed). Vol 4 "Influence of Tumor Development of the Host" (Herberman RB, vol ed), Dordrecht, Netherlands,-Kluwer Academic Publishers, pp 30-36, 1989.
29. Meins F Jr: Tumor reversal and tumor suppression in plants. In: Cancer Growth and Progression (Kaiser HE, series ed). Vol 4 "Influence of Tumor Development of the Host" (Herberman RB, vol ed), Dordrecht, Netherlands, Kluwer Academic Publishers, pp 37-41, 1989.
30. Xylander WER: Immune defense in arthropods - How chelicerates, crustaceans, insects and myriapods protect themselves against disease. Spiegel der Forschung 11: 27-30, 1994.
31. Papac RJ: Spontaneous regression of cancer. Cancer Treat Rev 22: 395-423, 1996.
32. Boyd W: The Spontaneous Regression of Cancer. Springfield, Charles C Thomas Publ, 1966.
33. Meares M: Regression of cancer after intensive meditation. Med J Austr 5: 184, 1976.
34. Meares M: Regression of osteogenic sarcoma metastases associated with intensive meditation. Med J Austr 2: 433, 1978.
35. Bennett WH: Some peculiarities in the behavior of certain malignant and innocent growths. Lancet 1: 3-7, 1899.
36. Cushing H, Wollbach SB: The transformation of a malignant paravertebral sympathicoblastoma into a benign ganglioneuroma. Am J Pathol 3: 203-216, 1927.
37. Bumpus HC Jr: The apparent disappearance, of pulmonary metastasis in a case of hypernephroma following nephrectomy. J Urol 20: 185-191, 1928.
38. O'Regan B, Hirschberg C: Spontaneous Remission. An Annotated Bibliography. Sausalito (CA, USA), Institute of Noetic Sciences, 1993.
39. Wells H: Chemical Pathology. Philadelphia, WB Saunders, 1925.
40. Glumac G, Mates A, Eidinger D: The heterocytotoxicity of human serum. III. Studies of the serum levels and distribution of activity in human populations. Clin Exp Immunol 26: 601-608, 1976.
41. Hellstrom KE, Hellstrom I: Spontaneous tumor regression: Possible relationships to in vitro parameters of tumor immunity. Natl Cancer Inst Monogr 44: 131-134, 1976.
42. Bolande RP, Todd EW: The cytotoxic action of normal human serum on certain cells propagated in vitro. AMA Arch Pathol 66: 720-732, 1958.
43. Bolande RP: Spontaneous regression of neuroblastoma: an experimental approach. Fed Pathol 10: 195-206, 1990.
44. Gross J, Simon E, Szwarc-Bilotynski L, Durst A, Pfefferman R, Polishuk Z: Complement-dependent lysis of Ehrlich ascites cells by human serum (ascitolysin) is lowered in cancer patients and raised in pregnant women. Eur J Cancer Clin Oncol 22: 13-19, 1986.
45. Bolande RP, Arnold JL, Mayer DC: Natural cytotoxicity of human serum. A natural IgM "antibody" sensitizes transformed murine cells to the lytic action of complement. Pathol Immunopathol Res 8: 46-60, 1989.
46. Evans AE, Gerson J, Schnaufer L: Spontaneous remission of neuroblastoma. Natl Cancer Irist Monogr 44: 49-54, 1976.
47. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF: Monoclonal antibodies to a glycolipid antigen of human neuroblastoma cells. Cancer Res 45: 2642-2649, 1985.
48. Saarinen UM, Coccia PF, Gerson SL, Peeley R, Cheung NK: Eradication of neuroblastoma cells in vitro by monoclonal antibodies and complement: Method for purging autologous bone marrow. Cancer Res 45: 5969-5975, 1985.
49. Carlsen NLT: How frequent is spontaneous remission of neuroblastomas? Implications for screening. Br J Cancer 61: 441-446, 1990.
50. Brodeur GM, Nakagawara A: Molecular basis of clinical heterogeneity in neuroblastoma. Am J Pediatr Hem Oncol 14: 111-116, 1992.
51. Tefany FJ, Bametson RS, Halliday GM, McCarthy SW, McCarthy WH: Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol 97: 197-202, 1991.
52. Baker HW: Biologic control of cancer. Arch Surg 121: 1237-1241, 1986.
53. Penn I: Cancers complicating organ transplantation. N Engl J Med 323: 1767-1769, 1990.
54. Horn L, Horn H: An immunologic approach to the treatment of cancer? Lancet 2: 466-469, 1971.
55. Cole WH: Efforts to explain spontaneous regression of cancer. J Surg Oncol 17: 201-209, 1981.
56. Rosenberg SA: Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. Important Adv Oncol, pp 55-91, 1986.
57. Sinkovics JG: Oncogenes and growth factors. CRC Critical Reviews in Immunology 8: 217-298, 1988.
58. Culliton BJ: Fighting cancer with designer cells. Science 244: 1430-1433, 1989.
59. Hersey P: Cellular therapy. Curr Opinion Oncol 5: 1049-1054, 1993.
60. Rosenberg SA, Terry W: Passive immunotherapy of cancer in animals and man. Adv Cancer Res 25: 323-388, 1977.
61. Rosenberg SA: Adoptive immunotherapy of cancer: accomplishments and prospects. Cancer Treat Rep 68: 233-255, 1984.
62. Sondel PM, Hank JA, Kohler PC, Chen BP, Sosman J: "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes. Prog Clin Biol Res 288: 151-160, 1989.
63. Katano M, Nagumo F, Kubota E, Yamamato H, Matsuo T, Hisatsagu T, Tadano J: Autologous tumour-specific cytotoxic T cell clone established from tumour infiltrating lymphocytes (TIL) of malignant ascites in the absence of recombinant interleukin 2 (rIL-2): activation by autologous tumour cell alone. Biotherapy 6: 25-32, 1993.
64. Bodey B, Bodey B Jr, Siegel SE: Immunophenotypic characterization of infiltrating poly- and mononuclear cells in childhood brain tumors. Mod Pathol 8: 333-338, 1995.
65. Bodey B, Bodey B Jr, Siegel SE, Luck JV, Kaiser HE: Immunophenotypic characterization of human primary and metastatic melanoma infiltrating autologous immunological effector cells. Anticancer Res 16: 3439-3446, 1996.
66. Hawkins MJ: Interleukin-2 antitumor and effector cell response. Semin Oncol 20(Suppl 9): 52-59, 1993.
67. Maccali C, Mortarini R, Parmiani G, Anichini A: Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles. Int J Cancer 57: 56-62, 1994.
68. Shi L, Kam CM, Powers JC, Aebersold R, Greenberg AH: Purification of three cytotoxic lymphocyte granule serine proteases that induce apoptosis through distinct substrate and target cell interactions. J Exp Med 176: 1521-1529, 1992.
69. Nagata S, Golstein P: The Fas death factor. Science 267: 1449-1456, 1995.
70. Khar A, Pardhasaradhi BVV, Varalakshmi Ch, Ali MA, Kumari AL: Natural killer cells as the effector which mediates in vivo apoptosis in AK-5 tumor cells. Cell Immunol 177: 86-92, 1997.
71. Trinchieri G: Biology of natural killer cells. Adv Immunol 47: 187-376, 1989.
72. Fesus L, Davies PJA, Piacentini M: Apoptosis: molecular mechanism in programmed cell death. Eur J Cell Biol 56: 170-177, 1991.
73. Hoon DB, Bowker RJ, Cochran AJ: Suppressor cell activity in melanoma-draining lymph nodes. Cancer Res 47: 1529-1533, 1987.
74. Shaw HM, McCarthy SW, McCarthy WH, Thompson JF, Milton GW: Thin regressing malignant melanoma: significance of concurrent regional lymph node metastases. Histopathology 15: 257-265, 1989.
75. Restifo NP, Kawakami Y, Marincola F, Shamamian P, Taggarse A, Esquivel F, Rosenberg SA: Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother 14: 182-190, 1993.
76. Schrier PI, Bernards R, Vaessen RTMJ, Houweling A, van der Eb AJ: Expression of class I major histocompatibility antigens switched off by highly oncogenic adenovirus 12 in transformed rat cells. Nature 305: 771-775, 1983.
77. Rooney CM, Rowe M, Wallace LE, Rickinson AB: Epstein-Barr virus positive Burkitt's lymphoma cells not recognized by virus specific T-cell surveillance. Nature 317: 629-631, 1985.
78. Weber JS, Kay G, Tanaka K, Rosenberg SA: Immunotherapy of a murine tumor with interleukin-2: increased sensitivity after MHC class I gene transfection. J Exp Med 166: 1716-1722, 1987.
79. Tanaka K, Yoshioka T, Bieberich C, Jay G: Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu Rev Immunol 6: 359-380, 1988.
80. Vujanovic NL, Nagashima S, Herberman RB, Whiteside TL: Nonsecretory apoptotic killing by human NK cells. J Immunol 157: 1117-1126, 1996.
81. Vujanovic NL, Basse P, Herberman RB, Whiteside TL: Antitumor functions of natural killer cells and control of metastases. Methods 9: 394-408, 1996.
82. Kradin RL, Xia W, Pike M, Byers HR, Pinto C: Interleukin-2 promotes the motility of dendritic cells and their accumulation in lung and skin. Pathobiology 64: 180-186, 1996.
83. Bodey B, Bodey B Jr, Kaiser HE: Dendritic type, accessory cells within the mammalian thymic microenvironment. Antigen presentation in the dendritic neuro-endocrine- immune cellular network. In Vivo 11: 351-370, 1997.
84. Underwood JC: Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br J Cancer 30: 538-548, 1974
85. Ioachim HL: The stromal reaction of tumors: an expression of - immune surveillance. J Natl Cancer Inst 57: 465-475, 1976.
86. Ruiter DJ, Bhan AK, Harrist TJ, Sober AJ, Mihm MC Jr: Major histocompatibility antigens and mononuclear inflammatory infiltrate in benign nevomelanocytic proliferations and malignant melanoma. J Immunol 129: 2808-2815, 1982.
87. Mikhail GR, Gorsulowsky DC: Spontaneous regression of metastatic malignant melanoma. Dermatol Surg Oncol 12: 497-500, 1986.
88. Herberman RB, Holden HT: Natural cell-mediated immunity. Adv Cancer Res 27: 305-337, 1978.
89. Nowell P: The clonal evolution of tumor cell populations. Science 194: 23-28, 1976.
90. Nicolson GL: Tumor cell instability, diversification and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 47: 1473-1487, 1987.
91. Corominas M, Leon J, Kamino H, Cruz-Alvarez M, Novick SC, Pellicer A. Oncogene involvement in tumor regression: H-ras activation in the rabbit keratoacanthoma model. Oncogene 6: 645-651, 1991.
92. Alexandrow MG, Moses HL: Transforming growth factor beta and cell cycle regulation. Cancer Res 55: 1452-1457, 1995.
93. Klein G: The approaching era of the tumor suppressor genes. Science 238: 1539-1545, 1987.
94. Barbacid M: ras genes. Annu Rev Biochem 56: 779-827, 1987.
95. Bos JL: The ras gene family and human carcinogenesis. Mutat Res 195: 255-271, 1988.
96. Bodey B, Bodey B Jr, Gröger AM, Luck JV, Siegel SE, Taylor CR, Kaiser HE: Clinical and prognostic significance of the expression of the c-erbB-2 and c-erbB-3 oncoproteins in primary and metastatic malignant melanomas and breast carcinomas. Anticancer Res 17: 1319-1330, 1997.
97. Hercbergs A, Leith JT: Spontaneous remission of metastatic lung cancer following myxedema coma - an apoptosis-related phenomenon? J Natl Cancer Inst 85: 1342-1343, 1993.
98. Bodey B, Bodey B Jr, Hall FL: Expression of Transforming Growth Factor-beta type II receptors in the cells of the human thymic microenvironment during ontogenesis. In: Molecular Biology of Hematopoiesis, Volume 5, Chapter 78 (Abraham NG, Asano S, Brittinger G, Maestroni GJM, Shadduck R, eds) New York, Plenum Press, pp 645-658, 1996.
99. Eaves C, Eaves A: Differential manipulation of normal and chronic myeloid leukemia stem cell proliferation in vitro. Blood Cells 20: 83-95, 1994.
100. Nathason L: Spontaneous regression of malignant melanoma: A review of the literature on incidence, clinical features, and possible mechanisms. Natl Cancer Inst Monogr 44: 67-76, 1976.
101. Birge RF, Jenks AL, Davis SK: Spontaneous remission in acute leukemia: Report of a case complicated with eclampsia. JAMA 140: 589-592, 1949.
102. Cantini E, James B: Acute myelogenous leukemia in pregnancy. South Med J 77: 1050-1052, 1984.
103. Smithers DW: Cancer of the breast and menopause. Clin Radiol 4: 89-96, 1952.
104. Lewison EF: Spontaneous regression of breast cancer. Natl Cancer Inst Monogr 44: 23-26, 1976.
105. Ross MB, Ross MB, Buzdar AU, Hortobagyi GN, Lukeman JM: Spontaneous regression of breast carcinoma: follow-up report and literature review. J Surg Oncol 19: 22-24, 1982.
106. Taetle R, Guittarad JP: Modulation of leukaemia blast colony growth by steroid hormones. Br J Haemat 50: 247-255, 1982.
107. Fisher RI, Neifeld JP, Lippman ME: Oestrogen receptors in human malignant melanoma. Lancet 2: 337-339, 1976.
108. Papac RJ, Kirkwood J: High dose tamoxifen in malignant melanoma. Cancer Treat Rep 67: 1049, 1993.
109. Walker MJ: Role of hormones and growth factors in melanomas. Semin Oncol 15: 512-523, 1988.
110. Jetten AM, Jetten MER: Possible role of retinoic acid binding protein in retinoid stimulation of embryonal carcinoma cell differentiation. Nature 278: 180-182, 1979.
111. Trown PW, Palleroni AV, Bohoslawec O, Richelo BN, Halpern JM, Gizzi N, Geiger R, Lewinski C, Machlin LJ, Jetten AM, Jetten MER: Relationship between binding affinities to cellular retinoic acid-binding protein and in vivo and in vitro properties for 18 retinoids. Cancer Res 40: 212-220, 1980.
112. Jetten AM, Deluca LM: Induction of differentiation of embryonal carcinoma cells by retinol: possible mechanisms. Biochem Biophys Res Commun 114: 593-599, 1983.
113. Eglitis MA, Sherman MI: Murine embryonal carcinoma cells differentiate in vitro in response to retinol. Exp Cell Res 146: 289-296, 1983.
114. Strickland S, Breitman TR, Frickel F, Nurrenbach A, Hadicke E, Sporn MB: Structure-activity relationships of a new series of retinoidal benzoic acid derivatives as measured by induction of differentiation of murine F9 teratocarcinoma cells and human HL-60 promyelocytic leukemia cells. Cancer Res 43: 5268-5272, 1983.
115. Jetten AM: Induction of differentiation of embryonal carcinoma cells by retinoids. In: Retinoids and Cell Differentiation (Sherman MI, ed). Boca Raton, CRC Press, p 105, 1986.
116. Jetten AM, Anderson K, Deas MA, Kagechika H, Lotan R, Rearick JI, Shudo K: New benzoic acid derivatives with retinoid activity: lack of direct correlation between biological activity and binding to cellular retinoic acid binding protein. Cancer Res 47: 3523-3527, 1987.
117. Giguere V, Ong ES, Segui P, Evans RM: Identification of a receptor for the morphogen retinoic acid. Nature 330: 624-629, 1987.
118. Pierce GB: Teratocarcinoma: model for a developmental concept of cancer. Curr Top Dev Biol 2: 223-246, 1967.
119. Sherman MI, Solter D (eds): Teratomas and Differentiation. New York, Academic Press, 1975.
120. Martin GR: Teratocarcinomas and mammalian embryogenesis. Science 209: 768-776, 1980.
121. Bolande RP: Models and concepts derived from human teratogenesis and oncogenesis in early life. J Histochem Cytochem 32: 878-884, 1984.
122. Astigiano S, Sherman MI, Abarzua P: Regulation and patterns of endogenous and exogenous gene expression during differentiation of embryonal carcinoma cells. Envir Health Persp 80: 25-38, 1989.
123. Strickland S, Mahdavi V: The induction of differentiation in teratocarcinoma stem cells by retinoic acid. Cell 15: 393-403, 1978.
124. Strickland S, Smith KK, Marotti KR: Hormonal induction of differentiation in teratocarcinoma stem cells: generation of parietal endoderm by retinoic acid and dibutyryl cAMP. Cell 21: 347-355, 1980.
125. Grover A, Oshima RG, Adamson ED: Epithelial layer formation in differentiating aggregates of F9 embryonal carcinoma cells. J Cell Biol 96: 1690-1696, 1983.
126. Grover A, Adamson ED: Evidence for the existence of an early common biochemical pathway in the differentiation of F9 cells into visceral or parietal endoderm: modulation by cyclic AMP. Dev Biol 114: 492-503, 1986.
127. Hong WK, Wittes RE, Hajdu ST, Cvitkovic E, Whitmore WF, Golbey RB: The evolution of mature teratoma from malignant testicular tumors. Cancer 40: 2987-2992, 1977.
128. Friedman SJ, Skehan P: Morphological differentiation of human choriocarcinoma cells induced by methotrexate. Cancer Res 39: 1960-1967, 1979.
129. Haas D, Ablin AR, Miller C, Zoger S, Matthay KK: Complete pathologic maturation and regression of stage IVS neuroblastoma without treatment. Cancer 62: 818-825, 1988.
130. Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L: All trans retinoic acid as differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 76: 1704-1709, 1990.
131. Kurie JM, Bosl GJ, Dmitrovsky ED: The genetic and biologic aspects of treatment response and resistance in male germ cell cancer. Semin Oncol 19: 197-205, 1992.
132. Stoll BA: Spontaneous regression of cancer: new insights. Biotherapy 4: 23-30, 1992.
133. Helmlinger G, Netti PA, Lichtenbeld HC, Melder RJ, Jain RK: Solid stress inhibits the growth of multicellular tumor spheroids. Nature Biotech 15: 778-783, 1997.
134. Fung YC: Biomechanical aspects of growth and tissue engineering. In: Biomechanics, motion, flow, stress, and growth. (Fung YC, ed) New York, Springer-Verlag, pp 499-546, 1990.
135. Vaage J: Fibrosis in immune control of mammary-tumor growth. Int J Cancer 51: 325-328, 1992.
136. Gartner MFRM, Feams C, Wilson EL, Campbell JAH, Dowdle EB: Unusual growth characteristics of human melanoma xenografts in the nude mouse: a model for desmoplasia, dormancy and progression. Br J Cancer 65: 487-490, 1992.
137. Young JS: The invasive growth of malignant tumours: an experimental interpretation based on elastic-jelly models. J Pathol Bact 77: 321-326, 1959.
138. Eaves G: The invasive growth of malignant tumours as a purely mechanical process. J Pathol 109: 233-237, 1973.
139. Falk P: Patterns of vasculature in two pairs of related fibrosarcomas in the rat and their relation to tumour responses to single large doses of radiation. Eur J Cancer 14: 237-250, 1978.
140. Falk P: The vascular pattern of the spontaneous C3H mouse mammary carcinoma and its significance in radiation response and in hyperthermia. Eur J Cancer 16: 203-217, 1980.
141. Tozer GM, Lewis S, Michalowski A, Aber V: The relationship between regional variations in blood flow and histology in a transplanted rat fibrosarcoma. Br J Cancer 61: 250-257, 1990.
142. Jain RK: Determinants of tumor blood flow: a review. Cancer Res 48: 2641-2658, 1988.
143. Li L, Price JE, Fan D, Zhang RD, Bucana CD, Fidler IJ: Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites. J Natl Cancer Inst 81: 1406-1412, 1989.
144. Sutherland RM: Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240: 177-184, 1988.
145. Farmilo AJ, Stead RH: Fixation in immunocytochemistry. In: Handbook Immunochemical Staining Methods. (Naish SJ, ed) DAKO Corporation, pp. 24-29, 1989.
146. Shi S-R, Key ME, Kalra KL: Antigen retrieval in formalin fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39: 741-748, 1991.
147. Shi S-R, Cote C, Kalra KL, Taylor CR, Tandon AK: A technique for retrieving antigens in formalin-fixed, routinely acid-decalcified, celloidin-embedded human temporal bone sections for immunohistochemistry. J Histochem Cytochem 40: 787-792, 1992.
148. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison of ABC and unlabeled antibody (PAP) procedure. J Histochem Cytochem 29: 577-581, 1981.
149. Janckila AJ, Yam LT, Li C-Y: Immunoalkaline phosphatase cytochemistry. Amer J Clin Pathol 84: 476-480, 1985.
150. Bodey B, Zeltzer PM, Saldivar V, Kemshead J: Immunophenotyping of childhood astrocytomas with a library of monoclonal antibodies. Int J Cancer 45: 1079-1087, 1990.
151. Yam LT, Janckila AJ, Epremian BE, Li C-Y: Diagnostic significance of levamisole-resistant alkaline phosphatase in cytochemistry and immunocytochemistry. Amer J Clin Pathol 91: 31-36, 1989.
152. Strasburger CJ, Amir-Zaltsman Y, Kohen F: The avidin-biotin reaction as an universal amplification system in immunoassays. Prog Clin Biol Res 285: 79-100, 1988.
153. Wilchek M, Bayer EA: Introduction to avidin-biotin technology. Methods Enzymol 184: 5-13, 1990.
154. Duhamel RC, Whitehead JS: Prevention of nonspecific binding of avidin. Methods Enzymol 184: 201-207, 1990.
155. Diamandis EP, Christopoulos TK: The biotin-(stiept)avidin system: principles and applications in biotechnology. Clin Chem 37: 625-636, 1991.
156. Battifora H: The multitumor (sausage) tissue block: novel method for immunohistochemical antibody testing. Lab Invest 55: 244-248, 1986.
157. Battifora H, Mehta P: The checkerboard tissue block. An improved multitissue control block. Lab Invest 63: 722-724, 1990.
158. Oldham RK, Lewko WM, Good RW, Sharp E: Cancer biotherapy with interferon, interleukin-2 and tumor-derived activated cells (TDAC). In Vivo 8: 653-663, 1994.
159. Pike M, Peters R, Cozen W, Probst-Hensch N, Felix J, Wan P, Mack T: Estrogen-Progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 89: 1110-1116, 1997.
160. Steinbrechner UP, Lisbona R, Huang SN, Mishkin S: Complete regression of hepatocellular adenoma after withdrawal of oral contraceptives. Dig Dis Sci 26: 1045-1050, 1981.
161. Tahara H, Shiozaki H, Kobayashi K, Yano T, Yano H, Tumnia S, Oku K, Miyata M, Wakasa K, Sakurai M: Phenotypic characteristics of tumour-infiltrating-lymphocytes in human oesophageal cancer tissues defined by quantitative two colour analysis with flow-cytometry. Virchows Arch 416: 329-334, 1990.
162. Belldegrun A, Kasid A, Uppenkamp M, Topalian SL, Rosenberg SA: Human tumor infiltrating lymphocytes. Analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol 142: 4520-4526, 1989.
163. Muul LM, Spiess PJ, Director EP, Rosenberg SA: Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol 101: 171-181, 1987.
164. Somers SS, Guillou PJ: Isolation and expansion of lymphocytes from gastrointestinal tumour tissue. Surg Oncol 2: 283-291, 1993.
165. Belldegrun A, Muul LM, Rosenberg SA: Interleukin-2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: Isolation, characterization, and antitumor activity. Cancer Res 48: 206-214, 1988.
166. + T lymphocytes admixed with irradiated tumor cells. Cancer Immunol Immunother 36: 323-330, 1993.
167. Rosenberg SA: The development of new immunotherapies for the treatment of cancer using interleukin-2. Am Surg 208: 121-135, 1988.
168. Haas GP, Solomon D, Rosenberg SA: Tumor infiltrating lymphocytes from non-renal urological malignancies. Cancer Immunol Immunother 30: 342-350, 1990.
169. Miescher S, Whiteside TL, Moretta L, von Fliedner V: Clonal and frequency analyses of tumor-infiltrating T lymphocytes from human solid tumors. J Immunol 138: 4004-4011, 1987.
170. Schiltz PM, Beutel LD, Nayak SK, Dillman RO: Characterization of tumor-infiltrating lymphocytes derived from hunan tumors for use as adoptive immunotherapy of cancer. J Immunother 20: 377-386, 1997.
171. Freedman RS, Tomasovic B, Templin S, Atkinson EN, Kudelka A, Edwards CL, Platsoucas CD: Large-scale expansion in interleukin-2 of tumor infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Methods 167: 145-160, 1994.
172. Freedman RS, Edwards CL, Kavanagh JJ, Kudelka AP, Katz RL, Carrasco CH, Atkinson EN, Scott W, Tomasovic B, Templin S, Platsoucas CD: Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial. J Immunother 16: 198-210, 1994.
173. Lewko WM, Good RW, Bowman D, Smith TL, Oldham RK: Growth of tumor derived activated T-cells for the treatment of cancer. Cancer Biotherapy 9: 211-224, 1994.
174. Topalian SL, Kasid A, Rosenberg SA: Immunoselection of a human melanoma resistant to specific lysis by autologous tumor-infiltrating lymphocytes. Possible mechanisms for immunotherapeutic failures. J Immunol 144: 4487-4495, 1990.
175. Beun GD, van de Velde CJ, Feuren GJ: T-cell based cancer immunotherapy: direct or redirected tumor-cell recognition? Immunol Today 15: 11-15, 1994.
176. Demanet C, Brissinck J, Leo O, Moser M, Thielemans K: Role of T-cell subsets in the bispecific antibody (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma. Cancer Res 54: 2973-2978, 1994.
177. Thibault C, Nelson H, Chapoval AI: Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies. Int J Cancer 67: 232-237, 1996.
178. Ferrini S, Cambiaggi A, Sforzini S, Canevari S, Mezzanzanica D, Colnaghi MI, Moretta L: Use of anti-CD3 and anti-CD16 bispecific monoclonal antibodies for the targeting of T and NK cells against tumor cells. Cancer Detect Prevent 17: 295-300, 1993.
179. Weiner LM, Holmes M, Adams GP, LaCreta F, Watts P, Garcia de Palazzo I: A human tumor xenograft model of therapy with a bispecific monoclonal antibody targeting c-erbB-2 and CD16. Cancer Res 53: 94-100, 1993.
180. Hombach A, Tillmann T, Jensen M, Heuser C, Sircar R, Diehl V, Kruis W, Pohl C: Specific activation of resting T cells against tumour cells by bispecific antibodies and CD28-mediated costimulation is accompanied by Th1 differentiation and recruitment of MHC-independent cytotoxicity. Clin Exp Immunol 108: 352-357, 1997.
181. Chapoval AI, Nelson H, Thibault C, Penna C, Dean P: Bifunctional antibody retargeting in vivo-activated T lymphocytes: simplifying clinical application. J Hematother 4: 571-577, 1995.
182. Csoka M, Strauss G, Debatin KM, Moldenhauer G: Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody. Leukemia 10: 1765-1772, 1996.
183. Demanet C, Brissinck J, De Jonge J, Thielemans K: Bispecific antibody-mediated immunotherapy of the BCL1 lymphoma: increased efficacy with multiple injections and CD28-induced costimulation. Blood 87: 4390-4398, 1996.
184. Haas C, Schirrmacher V: Immunogenicity increase of autologous tumor cell vaccines by virus infection and attachment of bispecific antibodies. Cancer Immunol Immunother 43: 190-194, 1996.
185. Holliger P, Brissinck J, Williams RL, Thielemans K, Winter G: Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng 9: 299-305, 1996.
186. Kroesen BJ, Wellenberg GJ, Bakker A, Helfrich W, The TH, de Leij L: The role of apoptosis in bispecific antibody-mediated T-cell cytotoxicity. Br J Cancer 73: 721-727, 1996.
187. Kuwahara M, Kuroki M, Arakawa F, Senba T, Matsuoka Y, Hideshima T, Yamashita Y, Kanda H: A mouse/human-chimeric bispecific antibody reactive with human carcinoembryonic antigen-expressing cells and human T-lymphocytes. Anticancer Res 16: 2661-2667, 1996.
188. Mack M, Gruber R, Schmidt S, Riethmuller G, Kufer P: Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. J Immunol 158: 3965-3970, 1997.
189. Renner C, Held G, Ohnesorge S, Bauer S, Gerlach K, Pfitzenmeier JP, Pfreundschuh M: Role of perform, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody-activated cytotoxic T cells. Cancer Immunol Immunother 44: 70-76, 1997.
190. Blaese RM, Mullen CA, Ramsey WJ: Strategies for gene therapy. Pathologie Biologie 41: 672-676, 1993.
191. Hwu P, Rosenberg SA: The Genetic Modification of T Cells for Cancer Therapy: An Overview of Laboratory and Clinical Trials. Cancer Detect Prevent 18: 43-50, 1994.
192. Kawakami Y, Rosenberg SA, Lotze MT: Interleukin-4 promotes the growth of tumor infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med 168: 2183-2191, 1988.
193. Kim TS, Cohen EP: MHC antigen expression by melanomas recovered from mice treated with allogeneic mouse fibroblasts genetically modified for interleukin-2 secretion and the expression of melanoma-associated antigens. Cancer Immunol Immunother 38: 185-193, 1994.
194. Abdel-Wahab Z, Weltz C, Hester D, Pickett N, Vervaert C, Barber JR, Jolly D, Seigler HFA: Phase I clinical trial of immunotherapy with interferon-gamma gene-modified autologous melanoma cells: monitoring the humoral immune response. Cancer 80: 401-412, 1997.
195. Jaffee EM, Pardoll DM: Considerations for the clinical development of cytokine gene-transduced tumor cell vaccines. Methods 12: 143-153, 1997.
196. Fearon ER, Pardoll DM, Itaya T, Golumbek PT, Levitsky HI, Simons JW, Karasuyma H, Vogelstein B, Frost P: IL-2 production by tumor cells bypasses T helper function in the generation of an anti-tumor response. Cell 60: 387-403, 1990.
197. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM: Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 254: 713-716, 1991.
198. Lipshy KA, Kostuchenko PJ, Hamad GG, Bland CE, Barrett SK, Bear HD: Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma. Ann Surg Oncol 4: 334-341, 1997.
199. Aruga E, Aruga A, Arca MJ, Lee WM, Yang NS, Smith JW 2nd, Chang AE: Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin 12, or GM-CSF. Cancer Gene Ther 4: 157-166, 1997.
200. Arienti F, Sule-Suso J, Belli F, Mascheroni L, Rivoltini L, Melani C, Maio M, Cascinelli N, Colombo MP, Parmiani G: Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Hum Gene Ther 7: 1955-1963, 1996.
201. Baskar S: Gene-modified tumor cells as cellular vaccine. Cancer Immunol Immunother 43: 165-173, 1996.
202. Dar MM, Abdel-Wahab Z, Vervaert CE, Darrow T, Barber J, Seigler HF: Immunological memory induced by genetically transduced tumor cells. Ann Surg Oncol 3: 247-254, 1996.
203. De Wit D, Flemming CL, Harris JD, Palmer KJ, Moore JS, Gore ME, Collins MK: IL-12 stimulation but not B7 expression increases melanoma, killing by patient cytotoxic T lymphocytes (CTL). Clin Exp Immunol 105: 353-359, 1996.
204. Dunussi-Joannopoulos K, Weinstein HJ, Nickerson PW, Strom TB, Burakoff SJ, Croop JM, Arceci RJ: Irradiated B7-1 transduced primary acute myelogenous leukemia (AML) cells can be used as therapeutic vaccines in murine AML. Blood 87: 2938-2946, 1996.
205. Knight BC, Souberbielle BE, Rizzardi GP, Ball SE, Dalgleish AG: Allogeneic murine melanoma cell vaccine: a model for the development of human allogeneic cancer vaccine. Melanoma Res 6: 299-306, 1996.
206. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guamieri F, Longo DL, Kwak LW: Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 156: 3858-3865, 1996.
207. Mule JJ, Custer M, Averbook B, Yang JC, Weber JS, Goeddel DV, Rosenberg SA, Schall TJ: RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum Gene Ther 7: 1545-1553, 1996.
208. Ohno K, Yoshizawa H, Tsukada H, Takeda T, Yamaguchi Y, Ichikawa K, Maruyama Y, Suzuki Y, Suzuki E, Arakawa M: Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells. J Immunol 156: 3875-3881, 1996.
209. Tung C, Federoff HJ, Brownlee M, Karpoff H, Weigel T, Brennan MF, Fong Y: Rapid production of interleukin-2-secreting tumor cells by herpes simplex virus-mediated gene transfer: implications for autologous vaccine production. Hum Gene Ther 7: 2217-2224, 1996.
210. Wakimoto H, Abe J, Tsunoda R, Aoyagi M, Hirakawa K, Hamada H: Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4. Cancer Res 56: 1828-1833, 1996.
211. Gaken JA, Hollingsworth SJ, Hirst WJ, Buggins AG, Galea-Lauri J, Peakman M, Kuiper M, Patel P, Towner P, Patel PM, Collins MK, Mufti GJ, Farzaneh F, Darling DC: Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors. Hum Gene Ther 8: 477-488, 1997.
212. Lee CT, Wu S, Ciernik IF, Chen H, Nadaf-Rahrov S, Gabrilovich D, Carbone DP: Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 8: 187-193, 1997.
213. Schmidt W, Maass G, Buschle M, Schweighoffer T, Berger M, Herbst E, Schilcher F, Bimstiel ML: Generation of effective cancer vaccines genetically engineered to secrete cytokines using adenovirus-enhanced transferrinfection (AVET). Gene 190: 211-216, 1997.
214. Nair SK, Snyder D, Rouse BT, Gilboa E: Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer 70: 706-715, 1997.
215. Sinkovics JG, Horvath J: New developments in the virus therapy of cancer: a historical review. Intervirology 36: 193-214, 1993.
216. Kasid A, Morecki S, Aebersold P, Cornetta K, Culver K, Freeman S, Director E, Lotze MT, Blaese RM, Anderson WF, Rosenberg SA: Human gene transfer: Characterization of human tumor-infiltrating lymphocytes as vehicles for retroviral-mediated gene transfer in man. Proc Natl Acad Sci USA 87: 473-477, 1990.
217. Abe J, Wakimoto H, Tsunoda R, Okabe S, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H: In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-gamma by adenovirus-mediated genetic transduction. Biochem Biophys Res Commun 218: 164-170, 1996.
218. Kordon RE, Schindhelm K: Ex vivo manipulation of cell subsets for cell therapies. Artif Organs 20: 396-402, 1996.
219. Tada M, Sawamura Y, Sakuma S, Suzuki K, Ohta H, Aida T, Abe H: Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor alpha for the treatment of malignant gliomas. Cancer Immunol Immunother 36: 251-259, 1993.
220. Moritz D, Groner B: A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther 2: 539-546, 1995.